Undiagnosed or poorly managed diabetes may be associated with several complications including cardiac ailments, lower limb amputations, blindness or renal disease. Projections state that India would lead this increasing public health concern with a staggering incidence of 134.3 million patients by the year, 2045 based on current trends. We utilized the FreeStyleLibre Pro Flash Glucose Monitoring (FGM) system, a novel automated ambulatory glucose profile (AGP) reporting system to identify precise hyperglycemic spikes in a specific patient population. There were 53 T2DM patients with an AGP-estimated HbA1c close to target levels (HbA1c between 7-8%). The 24-hour glycemic patterns were divided into 2-hour time slot patterns for review and analyses; thus, identifying precise spikes contributing to hyperglycemia in patients not achieving their target HbA1c. The highest glycemic peaks were observed between 10 am to 12noonand between 10 pm-12 am [mean interstitial glucose (mg/dL) ± SD of 204 ± 36 and 186 ± 23] coinciding with the post-breakfast and post-dinner periods, respectively. As shown in Table 1, the variation in glycemic spikes ofeach of the 2-hour slots was statistically significant (p<0.0001). FGM helped us identify glycemic variability and specifically, the contribution of post-breakfast hyperglycemia in precluding patients from achieving their target metabolic goals.
M.S. Chawla: Speaker's Bureau; Self; IPCA Laboratories, Eli Lilly and Company, Novo Nordisk A/S, MSD Pharmaceutical Pvt. Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. Speaker's Bureau; Spouse/Partner; Sanofi. P.M. Chawla: Speaker's Bureau; Self; Sanofi. Speaker's Bureau; Spouse/Partner; Eli Lilly and Company, IPCA LABORATORIES, Novo Nordisk A/S, MSD PHARMACEUTICALS PVT. LTD., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. M.C. Kothari: None. A.F. Shaikh: None. N. Wadhwa: None.